Effects of CoQ10, melatonin, vitamin B groups, vitamin D. and probiotic on reducing COVID-19 symptoms during recovery

Evaluating the Effects of CoQ10, melatonin, vitamin B groups, vitamin D. and probiotic on reducing COVID-19 symptoms during recovery- A randomized double blind controlled Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140804018677N21

Enrollment

Registered

2022-06-26

Start date

2022-05-05

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: 1000 mg capsul of CoQ10, melatonin, vitamin B groups, vitamin D. and probiotic capsule (Viralian Group company) BD for 30 days. Intervention 2: Control group: 1000

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed with COVID-19 according to WHO criteria Willing to participate in the study Age 18 years and older

Exclusion criteria

Exclusion criteria: Discharged with positive PCR test for COVID-19 Pregnancy Lactation Vitamin D deficiency based on lab test (<30 ng/ml) Enteral or parental nutrition requirement after discharge

Design outcomes

Primary

Measure	Time frame
Fatigue Severity. Timepoint: Baseline and at the end of the study. Method of measurement: Fatigue Severity Scale (FSS).;Sleep Quality. Timepoint: Baseline and at the end of the study. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).;Anxiety. Timepoint: Baseline and at the end of the study. Method of measurement: Hospital Anxiety and Depression Scale (HADS).;Constipation. Timepoint: Baseline and at the end of the study. Method of measurement: Patient Assessment of Constipation-Symptoms (PAC-SYM).;Headache severity. Timepoint: Baseline and at the end of the study. Method of measurement: Visual analog scale-VAS.;Headache duration. Timepoint: Baseline and at the end of the study. Method of measurement: Headache diary.;Headache Frequency. Timepoint: Baseline and at the end of the study. Method of measurement: Headache diary.	—

Measure

Time frame

Fatigue Severity. Timepoint: Baseline and at the end of the study. Method of measurement: Fatigue Severity Scale (FSS).;Sleep Quality. Timepoint: Baseline and at the end of the study. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).;Anxiety. Timepoint: Baseline and at the end of the study. Method of measurement: Hospital Anxiety and Depression Scale (HADS).;Constipation. Timepoint: Baseline and at the end of the study. Method of measurement: Patient Assessment of Constipation-Symptoms (PAC-SYM).;Headache severity. Timepoint: Baseline and at the end of the study. Method of measurement: Visual analog scale-VAS.;Headache duration. Timepoint: Baseline and at the end of the study. Method of measurement: Headache diary.;Headache Frequency. Timepoint: Baseline and at the end of the study. Method of measurement: Headache diary.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodeh Razghei Jahromi

Nutrition and food science faculty, Shahid Beheshti University of Medical Sciences

soodehrazeghi@gmail.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026